MedPath

Afami-cel Approval and Its Potential Influence on the Adoption of TCR Therapies

The approval of afamitresgene autoleucel (afami-cel) as the first T-cell receptor (TCR) therapy is seen as a pivotal milestone that could accelerate the development and acceptance of TCR-based treatments. This approval establishes a regulatory precedent, validates the therapeutic approach, and provides real-world evidence of safety and efficacy in treating solid tumors.

The recent approval of afamitresgene autoleucel (afami-cel) marks a significant milestone in the field of T-cell receptor (TCR) therapies. As the first TCR therapy to receive approval, afami-cel sets a regulatory precedent that could greatly influence the future development and acceptance of TCR-based treatments. This approval not only validates the therapeutic approach of TCR therapies but also provides crucial real-world evidence of their safety and efficacy, particularly in the treatment of solid tumors. The implications of this approval are vast, potentially accelerating the pace at which new TCR therapies are developed and adopted in clinical practice.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

FDA Approves Novel Therapies for Synovial Sarcoma, Cutaneous T-Cell Lymphoma, and Subcutaneous Atezolizumab

The FDA granted accelerated approval to Tecelra (afamitresgene autoleucel), a T-cell receptor therapy, for inoperable or metastatic synovial sarcoma, marking the first TCR therapy for solid tumors.
Lymphir (denileukin diftitox), a novel immunotherapy targeting the IL-2 receptor on malignant T cells, received FDA approval for relapsed or refractory cutaneous T-cell lymphoma.

FDA Approves Acoramidis (ATTRuby) for Transthyretin Amyloid Cardiomyopathy

The FDA has approved acoramidis (ATTRuby) by BridgeBio Pharma for treating transthyretin amyloid cardiomyopathy (ATTR-CM), offering a new treatment option.
Acoramidis is a near-complete TTR stabilizer (≥90%) and is approved to reduce cardiovascular death and cardiovascular-related hospitalization in ATTR-CM patients.

Acoramidis Approved for ATTR-CM, Showing Sustained Benefits in Long-Term Study

The FDA has approved acoramidis (Attruby) for transthyretin amyloid cardiomyopathy (ATTR-CM) to reduce cardiovascular death and hospitalization.
Acoramidis demonstrated a 42% reduction in all-cause mortality and cardiovascular-related hospitalization events compared to placebo at 30 months.

Adaptimmune's Lete-cel Shows Promise in Advanced Sarcomas, BLA Submission Planned

Adaptimmune's Lete-cel, a TCR-T cell therapy, demonstrated a 42% response rate in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma.
The median duration of response was 12.2 months, with manageable side effects like cytopenias and cytokine release syndrome.

MAGEA4-Targeted Therapies Show Promise in Solid Tumors Beyond Synovial Sarcoma

Afamitresgene autoleucel (afami-cel; Tecelra) received FDA approval for unresectable or metastatic synovial sarcoma, marking the first engineered cell therapy approval for a solid tumor.
MAGEA4, the target of afami-cel, is expressed in various solid tumors, including NSCLC, head and neck squamous cell carcinoma, and melanoma, making it a target for T-cell therapies.

FDA Approves Tecelra, a TCR-T Cell Therapy, Transforming Solid Tumor Treatment for Synovial Sarcoma

The FDA has approved Tecelra, a TCR-T cell therapy developed by Adaptimmune Therapeutics, marking the first TCR therapy for solid tumors, specifically unresectable or metastatic synovial sarcoma.
Tecelra targets the MAGE-A4 antigen, which is expressed in several tumors but absent in healthy tissues, offering a novel approach compared to CAR-T therapies by recognizing intracellular antigens.

FDA Roundup: TCR T-Cell Therapy Approved, CAR-T REMS Modified, and Clinical Holds Lifted

The FDA granted accelerated approval to Adaptimmune's afami-cel (Tecelra) for unresectable or metastatic synovial sarcoma in patients who have received prior chemotherapy.
Risk Evaluation and Mitigation Strategies (REMS) for autologous CAR-T immunotherapies were modified by the FDA to reduce the burden on healthcare systems.

Adaptimmune's Journey to Pioneering TCR-T Therapy for Cancer Treatment

Adaptimmune, a biotech company founded in 2008, has made significant strides in developing T-cell receptor (TCR)-T therapies for cancer. Despite challenges and rocky collaborations with pharmaceutical giants like GSK and Astellas, Adaptimmune achieved a major breakthrough with the FDA approval of its first engineered TCR-T therapy, afami-cel, for treating metastatic or unresectable synovial sarcoma. This approval marks several firsts in the field of cell therapy, offering new hope for patients with rare solid tumors.

FDA Approves Lifileucel (Amtagvi): First TIL Therapy for Melanoma

The FDA has granted accelerated approval to lifileucel (Amtagvi) for advanced melanoma after prior therapies, marking the first tumor-infiltrating lymphocyte (TIL) therapy approval.
Lifileucel is a personalized immunotherapy that uses a patient's own T cells extracted from their tumor to target and destroy cancer cells.

Adaptimmune Announces U.S. FDA Acceptance of Biologics License Application for Afami-cel

Adaptimmune Therapeutics plc has announced the U.S. FDA's acceptance for priority review of its Biologics License Application for afami-cel, an investigational engineered T-cell therapy for advanced synovial sarcoma, marking a significant step towards offering a new treatment option for this condition.

Reference News

[1]
Afami-cel Approval and Its Potential Influence on the Adoption of TCR Therapies - OncLive
onclive.com · Jan 14, 2025

Afamitresgene autoleucel (afami-cel) approval as the first TCR therapy is a milestone, potentially accelerating TCR-base...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy